Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10705302 | 0.94 | CAPN1 (0.52) | CAPN1TDP1KMT2ACTSKCTSS | |
| SCHEMBL25118682 | 0.94 | CAPN1 (0.52) | CAPN1TDP1KMT2ACTSKCTSS | |
| SCHEMBL24221821 | 0.88 | KMT2A (0.53) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL10481480 | 0.86 | CTSK (0.60) | CAPN1TDP1CTSKCTSSEPHX1 | |
| SCHEMBL10704556 | 0.86 | CTSK (0.60) | CAPN1TDP1CTSKCTSSEPHX1 | |
| SCHEMBL2946356 | 0.85 | TDP1 (0.57) | CAPN1TDP1KMT2ACTSKCTSS | |
| SCHEMBL22979065 | 0.85 | TDP1 (0.57) | CAPN1TDP1KMT2ACTSKCTSS | |
| SCHEMBL7102232 | 0.85 | CTSK (0.50) | CAPN1TDP1KMT2ACTSKCTSS | |
| SCHEMBL25449140 | 0.85 | CAPN1 (0.47) | CAPN1TDP1KMT2ACTSKCTSS | |
| SCHEMBL10421985 | 0.85 | CAPN1 (0.47) | CAPN1TDP1KMT2ACTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3395365-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-10-31 | — | — | EP | disclosed |
| WO-1990005141-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUKOCYTIC ELASTASE AND COLLAGENASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1990-05-17 | — | — | WO | disclosed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | disclosed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | disclosed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | MYD88, TLR9, IL2 | CAPN1 3304/4885TDP1 4542/4885KMT2A 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.